Historical Stock Chart
6 Months : From Dec 2018 to Jun 2019
Gibbs Law Group filed the only class action lawsuit to date against
Amarin Corporation (NASDAQ: AMRN). The suit is on behalf of investors
who purchased or acquired Amarin securities from September 24, 2018,
through November 8, 2018. The lawsuit seeks to recover damages for
Amarin investors under federal securities laws.
To speak privately with an attorney regarding this class action
lawsuit, call (800) 808-5294 or click
The class action lawsuit alleges that Amarin and certain of its officers
and directors made false and misleading statements or failed to disclose
that: (1) the top-line results Amarin touted about its REDUCE-IT trial
for Vascepa were not as positive as the company represented; (2) the
placebo given to patients in the control arm of REDUCE-IT may have
increased the incidence of cardiovascular events in those patients; (3)
as a result, Amarin’s public statements were materially false and
misleading at all relevant times.
If you suffered a loss in Amarin, you have until April 23, 2019, to
request that the Court appoint you as lead plaintiff. You do not need to
be a lead plaintiff in order to share in any recovery.
To speak privately with a securities attorney to learn more about our
investigation and your legal rights, visit our website
or contact our securities team directly at (800) 808-5294.
About Gibbs Law Group
Gibbs Law Group represents individual and institutional investors in securities
litigation, financial fraud and other complex litigation. We have
recovered over a billion dollars for its clients against some of the
world’s largest corporations, and our attorneys have received numerous
honors for their work, including “Best Lawyers in America,” “Top
Plaintiff Lawyers in California,” “Top Class Action Attorneys Under 40,”
“Consumer Protection MVP,” and “Top Cybersecurity/ Privacy Attorneys
This press release may constitute Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190301005561/en/